Cancer immunotherapy with the immune checkpoint blockade agents, such as PD-1/PD-L1 antibodies, has been widely used in the clinic against certain kinds of cancers.6 However, the effectiveness of these drugs in other cancers is still unsatisfactory. This evidence concerns the gene PDCD1 and cancer.